These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 22745104)

  • 1. Improved statistical modeling of tumor growth and treatment effect in preclinical animal studies with highly heterogeneous responses in vivo.
    Laajala TD; Corander J; Saarinen NM; Mäkelä K; Savolainen S; Suominen MI; Alhoniemi E; Mäkelä S; Poutanen M; Aittokallio T
    Clin Cancer Res; 2012 Aug; 18(16):4385-96. PubMed ID: 22745104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing cytotoxic treatment effects in preclinical tumor xenograft models.
    Wu J; Houghton PJ
    J Biopharm Stat; 2009 Sep; 19(5):755-62. PubMed ID: 20183441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal Design for Informative Protocols in Xenograft Tumor Growth Inhibition Experiments in Mice.
    Lestini G; Mentré F; Magni P
    AAPS J; 2016 Sep; 18(5):1233-1243. PubMed ID: 27306546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peginterferon Beta-1a Shows Antitumor Activity as a Single Agent and Enhances Efficacy of Standard of Care Cancer Therapeutics in Human Melanoma, Breast, Renal, and Colon Xenograft Models.
    Boccia A; Virata C; Lindner D; English N; Pathan N; Brickelmaier M; Hu X; Gardner JL; Peng L; Wang X; Zhang X; Yang L; Perron K; Yco G; Kelly R; Gamez J; Scripps T; Bennett D; Joseph IB; Baker DP
    J Interferon Cytokine Res; 2017 Jan; 37(1):20-31. PubMed ID: 27835061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker- versus drug-driven tumor growth inhibition models: an equivalence analysis.
    Sardu ML; Poggesi I; De Nicolao G
    J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):611-26. PubMed ID: 26209955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The design, analysis and application of mouse clinical trials in oncology drug development.
    Guo S; Jiang X; Mao B; Li QX
    BMC Cancer; 2019 Jul; 19(1):718. PubMed ID: 31331301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting.
    Oberg AL; Heinzen EP; Hou X; Al Hilli MM; Hurley RM; Wahner Hendrickson AE; Goergen KM; Larson MC; Becker MA; Eckel-Passow JE; Maurer MJ; Kaufmann SH; Haluska P; Weroha SJ
    Sci Rep; 2021 Apr; 11(1):8076. PubMed ID: 33850213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer.
    Freeman DJ; McDorman K; Ogbagabriel S; Kozlosky C; Yang BB; Doshi S; Perez-Ruxio JJ; Fanslow W; Starnes C; Radinsky R
    Mol Cancer; 2012 Jul; 11():47. PubMed ID: 22830443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A note on improved statistical approaches to account for pseudoprogression.
    Abrouk N; Oronsky B; Caroen S; Ning S; Knox S; Peehl D
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):621-626. PubMed ID: 29404682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the impact of HER2 status on the antitumor activity of an HSP90 inhibitor in human tumor xenograft mice using pharmacokinetic-pharmacodynamic modeling.
    Saitoh R; Nagayasu M; Shibahara N; Ono N; Suda A; Kato M; Ishigai M
    Drug Metab Pharmacokinet; 2014; 29(2):185-91. PubMed ID: 24126359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of antitumor activity for tumor xenograft studies using exponential growth models.
    Wu J
    J Biopharm Stat; 2011 May; 21(3):472-83. PubMed ID: 21442520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vivo Pharmacology Models for Cancer Target Research.
    Chen D; An X; Ouyang X; Cai J; Zhou D; Li QX
    Methods Mol Biol; 2019; 1953():183-211. PubMed ID: 30912023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new method for the high-precision assessment of tumor changes in response to treatment.
    Tar PD; Thacker NA; Babur M; Watson Y; Cheung S; Little RA; Gieling RG; Williams KJ; O'Connor JPB
    Bioinformatics; 2018 Aug; 34(15):2625-2633. PubMed ID: 29547950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors.
    Vaghi C; Rodallec A; Fanciullino R; Ciccolini J; Mochel JP; Mastri M; Poignard C; Ebos JML; Benzekry S
    PLoS Comput Biol; 2020 Feb; 16(2):e1007178. PubMed ID: 32097421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER
    Bihani T; Patel HK; Arlt H; Tao N; Jiang H; Brown JL; Purandare DM; Hattersley G; Garner F
    Clin Cancer Res; 2017 Aug; 23(16):4793-4804. PubMed ID: 28473534
    [No Abstract]   [Full Text] [Related]  

  • 16. Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects.
    Zegers CM; Rekers NH; Quaden DH; Lieuwes NG; Yaromina A; Germeraad WT; Wieten L; Biessen EA; Boon L; Neri D; Troost EG; Dubois LJ; Lambin P
    Clin Cancer Res; 2015 Mar; 21(5):1151-60. PubMed ID: 25552483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
    Garrett LA; Growdon WB; Rueda BR; Foster R
    J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical evaluation of biomarkers for response monitoring to the MET inhibitor BAY-853474.
    Klotz M; Schmid E; Steiner-Hahn K; Rose T; Laube J; Roese L; Henderson D; Krahn T; von Ahsen O
    Biomarkers; 2012 Jun; 17(4):325-35. PubMed ID: 22452362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib.
    Yamazaki S
    AAPS J; 2013 Apr; 15(2):354-66. PubMed ID: 23250669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and preclinical characterization of a humanized antibody targeting CXCL12.
    Zhong C; Wang J; Li B; Xiang H; Ultsch M; Coons M; Wong T; Chiang NY; Clark S; Clark R; Quintana L; Gribling P; Suto E; Barck K; Corpuz R; Yao J; Takkar R; Lee WP; Damico-Beyer LA; Carano RD; Adams C; Kelley RF; Wang W; Ferrara N
    Clin Cancer Res; 2013 Aug; 19(16):4433-45. PubMed ID: 23812669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.